Related Experiment Videos
Induction of activated macrophages by intraperitoneal injection of mitomycin C in mice
Abstract:
The host cellular response to IP injection of mitomycin C was studied in C3H/HeN mice. As assessed by in vitro cytolysis assay using 125I-iododeoxyuridine-labelled tumour target cells, mitomycin C-induced peritoneal macrophages showed the maximum tumouricidal activity 4 days after the IP injection. The tumouricidal activity was dependent on the dose of mitomycin C injected and it was detectable against syngeneic, allogeneic and xenogeneic tumour target cells. In addition, these tumouricidal macrophages were found to be augmented in functions of both incorporation of 2-deoxy-D-glucose and phagocytosis of sheep red blood cells. Among the other anti-cancer drugs, which were used at a dose of three-fifths of LD50, only adriamycin (7.5 mg/kg) was capable of inducing activated macrophages as much as mitomycin C (3 mg/kg). Cyclophosphamide (225 mg/kg), methotrexate (60 mg/kg) and vincristine (1.5 mg/kg) were able to augment incorporation of 2-deoxy-D-glucose and phagocytosis of sheep red blood cells, but not tumouricidal activity. Differential cytolysis assay was performed for two cell lines of P 388 tumour target cells, the mitomycin C-sensitive original cell line and the mitomycin C-resistant subline, demonstrating no significant difference in macrophage-mediated tumour cell lysis between these cell lines. Based on these results, it was concluded that mitomycin C, when injected IP induced activated macrophages in the peritoneal cavity. A better understanding of the effect of anti-cancer drugs on macrophage tumouricidal activity may be useful in designing more effective local chemotherapy for malignant peritoneal effusions.
Insights
Intraperitoneal injection of mitomycin C activates mouse macrophages, enhancing their tumor-killing ability. This effect, observed in mice, suggests potential for localized chemotherapy against peritoneal cancers.
Area of Science:
- Immunology
- Pharmacology
- Oncology
Background:
- Host cellular responses to chemotherapy are crucial for treatment efficacy.
- Macrophages play a key role in anti-tumor immunity and can be activated by certain drugs.
- Understanding drug-induced macrophage activation is vital for developing novel cancer therapies.
Purpose of the Study:
- To investigate the host cellular response to intraperitoneal (IP) mitomycin C in mice.
- To assess the impact of mitomycin C on peritoneal macrophage tumoricidal activity.
- To compare the macrophage-activating potential of mitomycin C with other anti-cancer drugs.
Main Methods:
- In vitro cytolysis assay using 125I-iododeoxyuridine-labeled tumor target cells.
- Assessment of macrophage functions including glucose uptake and phagocytosis.
- Differential cytolysis assay on mitomycin C-sensitive and resistant tumor cell lines.
Main Results:
- IP mitomycin C induced peritoneal macrophages with maximum tumoricidal activity 4 days post-injection.
- Macrophage tumoricidal activity was dose-dependent and effective against various tumor types.
- Mitomycin C and adriamycin significantly enhanced macrophage tumoricidal activity, unlike cyclophosphamide, methotrexate, or vincristine.
- Activated macrophages showed augmented glucose uptake and phagocytosis.
Conclusions:
- Intraperitoneal mitomycin C effectively induces activated macrophages in the peritoneal cavity.
- Activated macrophages exhibit enhanced tumoricidal activity and functional augmentation.
- Further research into drug-modulated macrophage activity could inform local chemotherapy strategies for malignant peritoneal effusions.